II. Mechanism
- Extraction of WBCs via Leukapheresis- White Blood Cells (including T Cells) extracted from patient's blood and T Cells are concentrated
- White cells of interest for re-engineering- Natural Killer Cells (NK cells)
- Lymphokine-activated Killer T Cells
- Cytotoxic T cells
- Dendritic Cells
 
 
- Reprogramming
- Multiplication- Engineered CAR T Cells are multiplied in a bioreactor
 
- Preparation with lymphodepletion- Patient is administered Chemotherapy to suppress their own White Blood Cells
 
- Treatment- Engineered CAR T Cells are infused into the patient
- T Cells recognize target Antigens and destroy cancer cells- Sensitization to additional cancer cell components (cross-prime), providing additional cancer destruction
 
 
III. Medications: CD19 Cell Surface Targets
- Tisagenlecleucel- B Cell Acute Lymphoblastic Leukemia
 
- Axicabtagene ciloleucel- B Cell Lymphoma subtypes
 
IV. Adverse Effects
- See Cytokine Release Syndrome (CRS)
- Neurotoxicity- Signs- Headache
- Expressive Aphasia
- Confusion to Delirium
- Seziures (including nonconvulsive Status Epilepticus in 10% of cases)
- Cerebral edema
- Encephalopathy (CAR T Cell-related encephalopathy or CRES)
 
- Management- Seizure Prophylaxis
- Corticosteroids may be more effective than Tocilizumab (see dosing under CRS as above)
 
 
- Signs
- On-Target/Off Tumor Recognition- T Cell attacks noncancerous cells displaying target Antigen
 
V. References
- Jansson and Pallin (2020) Crit Dec Emerg Med 34(4): 19-28
- Santomasso (2019) Am Soc Clin Oncol Educ Book 39:433-444
